Diclegis: Drug Makes 30-Year Comeback

— Class A morning sickness medication gains FDA approval after decades of being misunderstood.

MedpageToday

Long out of favor, the combination of pyridoxine and doxylamine is now available as Diclegis as a treatment for pregnancy-related gastric distress. The prescription version is very costly but a much cheaper over-the-counter alternative may serve for many patients.

Notable History

Pyridoxine/doxylamine was first marketed in the U.S. in 1956 as Bendectin. Unfortunately, a string of lawsuits were brought against its manufacturer, claiming Bendectin caused fetal malformations. Even though the lawsuits were nonmeritorious, the legal costs of going to trial were enough to drive the company out of business and the medication was voluntarily pulled from the market in 1983. The FDA never found any link between Bendectin and fetal malformations, and in at least one major lawsuit, teratogenicity data were later found to have been falsified. Despite this, no new medications for nausea in pregnancy were approved for 30 years. After its withdrawal from the market the frequency of hospitalization for nausea and vomiting in pregnancy doubled. In other countries the combination has still been used, and many obstetricians in the U.S. have continued to recommend it off-label. In 2013 the FDA approved a new combination pill made by a Canadian company, marketed as Diclegis.

Major Indications

Diclegis is used for pregnancy-associated nausea and vomiting. Certain patients respond well to ondansetron (Zofran), which is a common first-line agent for nausea in the emergency department. However, ondansetron is ineffective for some pregnant patients, and is cost-prohibitive to take at home for others. Pyridoxine/doxylamine is a safe medication for pregnant patients (Class A), and may provide superior symptom relief in some cases.

How It Works

The exact mechanism of action of pyridoxine is unclear. Doxylamine is an antihistamine active on central and peripheral H1 receptors. It acts on the chemoreceptor trigger zone to reduce nausea.

Adverse Events

The most common side effect is drowsiness (occurring in 14% of patients), a result of the central antihistamine activity. Serious side effects are extremely rare. Patients should be instructed to take the medication at night when starting it, and to use caution if taking it prior to driving or operating machinery.

Cautions

Pyridoxine/doxylamine bears the remarkable pregnancy safety rating of Class A and has been studied in more pregnant patients than any other medication. In fact, according to the American College of Obstetricians and Gynecologists, "taking Vitamin B6 plus doxylamine is safe and should be considered a first-line treatment." By comparison, other commonly used medications such as ondansetron and promethazine (Phenergan) are Class C, and metoclopramide (Reglan) is class B.

Dose Adjustments

One tablet contains 10 mg of pyridoxine and 10 mg of doxylamine. Patients can take two to four tablets daily. The recommended starting dose is two tablets taken at night, since the main side effect is sleepiness. If this is ineffective, patients can add a tablet in the morning, and then another tablet in the afternoon. Unlike ondansetron or promethazine that can be taken on a PRN basis, however, pyridoxine/doxylamine should be taken on a daily, scheduled basis to be effective. There are no renal or hepatic dosing adjustments defined.

Special Features

The drug combination can also be made from over-the-counter versions of pyridoxine (vitamin B6) and doxylamine (Unisom). Or it can be given as prescription Diclegis.

Cost

Prescription Diclegis (10 mg pyridoxine/10 mg doxylamine) costs around $570 for 100 tablets. Many patients may require two to four tablets per day. Over-the-counter 25 mg pyridoxine and 20 mg doxylamine each cost $5 to $10 for 100 tablets. The prescription version may be cost-prohibitive for some patients, in which case the over-the-counter combination is a viable alternative.

Christina Shenvi, MD, PhD, is an assistant professor in the department of emergency medicine at the University of North Carolina. A version of this article originally appeared at Emergency Physicians Monthly.